- Home
- PHAT vs ARCT Comparison
PHAT vs ARCT Comparison
Compare PHAT & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ARCT
- Stock Information
- Founded
- PHAT 2018
- ARCT 2013
- Country
- PHAT United States
- ARCT United States
- Employees
- PHAT N/A
- ARCT N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- ARCT Health Care
- Exchange
- PHAT Nasdaq
- ARCT Nasdaq
- Market Cap
- PHAT 289.0M
- ARCT 298.3M
- IPO Year
- PHAT 2019
- ARCT N/A
- Fundamental
- Price
- PHAT $8.92
- ARCT $12.79
- Analyst Decision
- PHAT Strong Buy
- ARCT Strong Buy
- Analyst Count
- PHAT 4
- ARCT 8
- Target Price
- PHAT $16.25
- ARCT $52.33
- AVG Volume (30 Days)
- PHAT 4.4M
- ARCT 497.4K
- Earning Date
- PHAT 05-01-2025
- ARCT 08-04-2025
- Dividend Yield
- PHAT N/A
- ARCT N/A
- EPS Growth
- PHAT N/A
- ARCT N/A
- EPS
- PHAT N/A
- ARCT N/A
- Revenue
- PHAT $81,859,000.00
- ARCT $143,680,000.00
- Revenue This Year
- PHAT $195.45
- ARCT N/A
- Revenue Next Year
- PHAT $106.76
- ARCT $39.32
- P/E Ratio
- PHAT N/A
- ARCT N/A
- Revenue Growth
- PHAT 3055.70
- ARCT 15.38
- 52 Week Low
- PHAT $2.21
- ARCT $8.04
- 52 Week High
- PHAT $19.71
- ARCT $44.22
- Technical
- Relative Strength Index (RSI)
- PHAT 82.93
- ARCT 54.96
- Support Level
- PHAT $4.47
- ARCT $11.83
- Resistance Level
- PHAT $4.99
- ARCT $13.27
- Average True Range (ATR)
- PHAT 0.89
- ARCT 0.86
- MACD
- PHAT 0.39
- ARCT 0.03
- Stochastic Oscillator
- PHAT 60.60
- ARCT 61.61
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.